ID   PAK2_HUMAN              Reviewed;         524 AA.
AC   Q13177; Q13154; Q6ISC3;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   03-APR-2007, sequence version 3.
DT   12-OCT-2022, entry version 226.
DE   RecName: Full=Serine/threonine-protein kinase PAK 2;
DE            EC=2.7.11.1 {ECO:0000269|PubMed:15234964, ECO:0000269|PubMed:21177766, ECO:0000269|PubMed:21317288, ECO:0000269|PubMed:21555521, ECO:0000269|PubMed:21724829};
DE   AltName: Full=Gamma-PAK;
DE   AltName: Full=PAK65;
DE   AltName: Full=S6/H4 kinase;
DE   AltName: Full=p21-activated kinase 2;
DE            Short=PAK-2;
DE   AltName: Full=p58;
DE   Contains:
DE     RecName: Full=PAK-2p27;
DE              Short=p27;
DE   Contains:
DE     RecName: Full=PAK-2p34;
DE              Short=p34;
DE     AltName: Full=C-t-PAK2;
GN   Name=PAK2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RA   Sells M., Knause U.J., Bagrodia S., Ambrose D., Bokoch G.M., Chernoff J.;
RL   Submitted (APR-1995) to the EMBL/GenBank/DDBJ databases.
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 32-524, PROTEIN SEQUENCE OF 401-417,
RP   FUNCTION, AND TISSUE SPECIFICITY.
RC   TISSUE=Placenta;
RX   PubMed=7744004; DOI=10.1002/j.1460-2075.1995.tb07189.x;
RA   Martin G.A., Bollag G., McCormick F., Abo A.;
RT   "A novel serine kinase activated by rac1/CDC42Hs-dependent
RT   autophosphorylation is related to PAK65 and STE20.";
RL   EMBO J. 14:1970-1978(1995).
RN   [4]
RP   ERRATUM OF PUBMED:7744004.
RX   PubMed=7556080; DOI=10.1002/j.1460-2075.1995.tb00113.x;
RA   Martin G.A., Bollag G., McCormick F., Abo A.;
RL   EMBO J. 14:4385-4385(1995).
RN   [5]
RP   AUTOPHOSPHORYLATION.
RX   PubMed=7673144; DOI=10.1074/jbc.270.36.21121;
RA   Benner G.E., Dennis P.B., Masaracchia R.A.;
RT   "Activation of an S6/H4 kinase (PAK 65) from human placenta by
RT   intramolecular and intermolecular autophosphorylation.";
RL   J. Biol. Chem. 270:21121-21128(1995).
RN   [6]
RP   PROTEOLYTIC CLEAVAGE AT ASP-212 BY CASPASE-3, FUNCTION, AND MUTAGENESIS OF
RP   ASP-212.
RX   PubMed=9171063; DOI=10.1126/science.276.5318.1571;
RA   Rudel T., Bokoch G.M.;
RT   "Membrane and morphological changes in apoptotic cells regulated by
RT   caspase-mediated activation of PAK2.";
RL   Science 276:1571-1574(1997).
RN   [7]
RP   PROTEOLYTIC CLEAVAGE AT ASP-212 BY CASPASE-3, AUTOPHOSPHORYLATION,
RP   PHOSPHORYLATION AT THR-402, AND MUTAGENESIS OF LYS-278 AND THR-402.
RX   PubMed=9786869; DOI=10.1074/jbc.273.44.28733;
RA   Walter B.N., Huang Z., Jakobi R., Tuazon P.T., Alnemri E.S., Litwack G.,
RA   Traugh J.A.;
RT   "Cleavage and activation of p21-activated protein kinase gamma-PAK by CPP32
RT   (caspase 3). Effects of autophosphorylation on activity.";
RL   J. Biol. Chem. 273:28733-28739(1998).
RN   [8]
RP   INTERACTION WITH HIV-1 NEF (MICROBIAL INFECTION).
RX   PubMed=11070003; DOI=10.1128/jvi.74.23.11081-11087.2000;
RA   Arora V.K., Molina R.P., Foster J.L., Blakemore J.L., Chernoff J.,
RA   Fredericksen B.L., Garcia J.V.;
RT   "Lentivirus Nef specifically activates Pak2.";
RL   J. Virol. 74:11081-11087(2000).
RN   [9]
RP   FUNCTION (PAK-2P34), UBIQUITINATION, SUBCELLULAR LOCATION, AND MUTAGENESIS
RP   OF 239-ILE--GLY-243 AND 246-LYS--LYS-248.
RX   PubMed=12853446; DOI=10.1074/jbc.m306494200;
RA   Jakobi R., McCarthy C.C., Koeppel M.A., Stringer D.K.;
RT   "Caspase-activated PAK-2 is regulated by subcellular targeting and
RT   proteasomal degradation.";
RL   J. Biol. Chem. 278:38675-38685(2003).
RN   [10]
RP   FUNCTION IN PHOSPHORYLATION OF MKNK1, AND CATALYTIC ACTIVITY.
RX   PubMed=15234964; DOI=10.1074/jbc.m407337200;
RA   Orton K.C., Ling J., Waskiewicz A.J., Cooper J.A., Merrick W.C.,
RA   Korneeva N.L., Rhoads R.E., Sonenberg N., Traugh J.A.;
RT   "Phosphorylation of Mnk1 by caspase-activated Pak2/gamma-PAK inhibits
RT   phosphorylation and interaction of eIF4G with Mnk.";
RL   J. Biol. Chem. 279:38649-38657(2004).
RN   [11]
RP   INTERACTION WITH ARHGAP10, AND SUBCELLULAR LOCATION.
RX   PubMed=15471851; DOI=10.1074/jbc.m410530200;
RA   Koeppel M.A., McCarthy C.C., Moertl E., Jakobi R.;
RT   "Identification and characterization of PS-GAP as a novel regulator of
RT   caspase-activated PAK-2.";
RL   J. Biol. Chem. 279:53653-53664(2004).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in signaling
RT   networks.";
RL   Cell 127:635-648(2006).
RN   [13]
RP   INTERACTION WITH SH3MD4.
RX   PubMed=16374509; DOI=10.1038/sj.embor.7400596;
RA   Kaerkkaeinen S., Hiipakka M., Wang J.-H., Kleino I., Vaehae-Jaakkola M.,
RA   Renkema G.H., Liss M., Wagner R., Saksela K.;
RT   "Identification of preferred protein interactions by phage-display of the
RT   human Src homology-3 proteome.";
RL   EMBO Rep. 7:186-191(2006).
RN   [14]
RP   FUNCTION (PAK-2P34), MYRISTOYLATION AT GLY-213 (PAK-2P34), SUBCELLULAR
RP   LOCATION, AND MUTAGENESIS OF GLY-213.
RX   PubMed=16617111; DOI=10.1073/pnas.0600824103;
RA   Vilas G.L., Corvi M.M., Plummer G.J., Seime A.M., Lambkin G.R.,
RA   Berthiaume L.G.;
RT   "Posttranslational myristoylation of caspase-activated p21-activated
RT   protein kinase 2 (PAK2) potentiates late apoptotic events.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:6542-6547(2006).
RN   [15]
RP   INTERACTION WITH SCRIB.
RX   PubMed=18716323; DOI=10.1093/hmg/ddn248;
RA   Nola S., Sebbagh M., Marchetto S., Osmani N., Nourry C., Audebert S.,
RA   Navarro C., Rachel R., Montcouquiol M., Sans N., Etienne-Manneville S.,
RA   Borg J.-P., Santoni M.-J.;
RT   "Scrib regulates PAK activity during the cell migration process.";
RL   Hum. Mol. Genet. 17:3552-3565(2008).
RN   [16]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Platelet;
RX   PubMed=18088087; DOI=10.1021/pr0704130;
RA   Zahedi R.P., Lewandrowski U., Wiesner J., Wortelkamp S., Moebius J.,
RA   Schuetz C., Walter U., Gambaryan S., Sickmann A.;
RT   "Phosphoproteome of resting human platelets.";
RL   J. Proteome Res. 7:526-534(2008).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-58; SER-141 AND THR-169, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [18]
RP   FUNCTION, AND INTERACTION WITH ARHGEF7 AND GIT1.
RX   PubMed=19273597; DOI=10.1128/mcb.01713-08;
RA   Mitsushima M., Toyoshima F., Nishida E.;
RT   "Dual role of Cdc42 in spindle orientation control of adherent cells.";
RL   Mol. Cell. Biol. 29:2816-2827(2009).
RN   [19]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-141 AND SER-197, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [20]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-128, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C.,
RA   Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [21]
RP   INTERACTION WITH RAC1.
RX   PubMed=20696164; DOI=10.1016/j.febslet.2010.07.060;
RA   Kaerkkaeinen S., van der Linden M., Renkema G.H.;
RT   "POSH2 is a RING finger E3 ligase with Rac1 binding activity through a
RT   partial CRIB domain.";
RL   FEBS Lett. 584:3867-3872(2010).
RN   [22]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=19923322; DOI=10.1091/mbc.e09-03-0232;
RA   Hsu R.M., Tsai M.H., Hsieh Y.J., Lyu P.C., Yu J.S.;
RT   "Identification of MYO18A as a novel interacting partner of the
RT   PAK2/betaPIX/GIT1 complex and its potential function in modulating
RT   epithelial cell migration.";
RL   Mol. Biol. Cell 21:287-301(2010).
RN   [23]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2, PHOSPHORYLATION [LARGE SCALE
RP   ANALYSIS] AT SER-2 AND SER-141, CLEAVAGE OF INITIATOR METHIONINE [LARGE
RP   SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [24]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [25]
RP   AUTOPHOSPHORYLATION.
RX   PubMed=21098037; DOI=10.1074/jbc.m110.156505;
RA   Wang J., Wu J.W., Wang Z.X.;
RT   "Mechanistic studies of the autoactivation of PAK2: a two-step model of cis
RT   initiation followed by trans amplification.";
RL   J. Biol. Chem. 286:2689-2695(2011).
RN   [26]
RP   FUNCTION IN PHOSPHORYLATION OF MAPK4 AND MAPK6, AND CATALYTIC ACTIVITY.
RX   PubMed=21317288; DOI=10.1074/jbc.m110.181743;
RA   De la Mota-Peynado A., Chernoff J., Beeser A.;
RT   "Identification of the atypical MAPK Erk3 as a novel substrate for p21-
RT   activated kinase (Pak) activity.";
RL   J. Biol. Chem. 286:13603-13611(2011).
RN   [27]
RP   FUNCTION IN PHOSPHORYLATION OF CASP7, CATALYTIC ACTIVITY, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=21555521; DOI=10.1074/jbc.m111.236596;
RA   Li X., Wen W., Liu K., Zhu F., Malakhova M., Peng C., Li T., Kim H.G.,
RA   Ma W., Cho Y.Y., Bode A.M., Dong Z., Dong Z.;
RT   "Phosphorylation of caspase-7 by p21-activated protein kinase (PAK) 2
RT   inhibits chemotherapeutic drug-induced apoptosis of breast cancer cell
RT   lines.";
RL   J. Biol. Chem. 286:22291-22299(2011).
RN   [28]
RP   FUNCTION IN PHOSPHORYLATION OF JUN, AND CATALYTIC ACTIVITY.
RX   PubMed=21177766; DOI=10.1093/carcin/bgq271;
RA   Li T., Zhang J., Zhu F., Wen W., Zykova T., Li X., Liu K., Peng C., Ma W.,
RA   Shi G., Dong Z., Bode A.M., Dong Z.;
RT   "P21-activated protein kinase (PAK2)-mediated c-Jun phosphorylation at 5
RT   threonine sites promotes cell transformation.";
RL   Carcinogenesis 32:659-666(2011).
RN   [29]
RP   FUNCTION IN PHOSPHORYLATION OF HISTONE H4, AND CATALYTIC ACTIVITY.
RX   PubMed=21724829; DOI=10.1101/gad.2055511;
RA   Kang B., Pu M., Hu G., Wen W., Dong Z., Zhao K., Stillman B., Zhang Z.;
RT   "Phosphorylation of H4 Ser 47 promotes HIRA-mediated nucleosome assembly.";
RL   Genes Dev. 25:1359-1364(2011).
RN   [30]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2, PHOSPHORYLATION [LARGE SCALE
RP   ANALYSIS] AT SER-2; SER-141 AND THR-169, CLEAVAGE OF INITIATOR METHIONINE
RP   [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE
RP   SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [31]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=22223895; DOI=10.1074/mcp.m111.015131;
RA   Bienvenut W.V., Sumpton D., Martinez A., Lilla S., Espagne C., Meinnel T.,
RA   Giglione C.;
RT   "Comparative large-scale characterisation of plant vs. mammal proteins
RT   reveals similar and idiosyncratic N-alpha acetylation features.";
RL   Mol. Cell. Proteomics 11:M111.015131-M111.015131(2012).
RN   [32]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E.,
RA   Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-terminal
RT   acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [33]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2; SER-20; SER-55; SER-58;
RP   THR-60; SER-64; THR-134; SER-141; THR-143; THR-154; THR-169 AND SER-197,
RP   AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [34]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-139 AND SER-141, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [35]
RP   FUNCTION IN PHOSPHORYLATION OF CASP7, AND CATALYTIC ACTIVITY.
RX   PubMed=27889207; DOI=10.1016/j.str.2016.11.001;
RA   Eron S.J., Raghupathi K., Hardy J.A.;
RT   "Dual site phosphorylation of caspase-7 by PAK2 blocks apoptotic activity
RT   by two distinct mechanisms.";
RL   Structure 25:27-39(2017).
RN   [36]
RP   X-RAY CRYSTALLOGRAPHY (2.86 ANGSTROMS) OF 121-136.
RX   PubMed=21170023; DOI=10.1038/nature09593;
RA   Selyunin A.S., Sutton S.E., Weigele B.A., Reddick L.E., Orchard R.C.,
RA   Bresson S.M., Tomchick D.R., Alto N.M.;
RT   "The assembly of a GTPase-kinase signalling complex by a bacterial
RT   catalytic scaffold.";
RL   Nature 469:107-111(2011).
CC   -!- FUNCTION: Serine/threonine protein kinase that plays a role in a
CC       variety of different signaling pathways including cytoskeleton
CC       regulation, cell motility, cell cycle progression, apoptosis or
CC       proliferation (PubMed:7744004, PubMed:19273597, PubMed:19923322,
CC       PubMed:9171063, PubMed:12853446, PubMed:16617111). Acts as downstream
CC       effector of the small GTPases CDC42 and RAC1 (PubMed:7744004).
CC       Activation by the binding of active CDC42 and RAC1 results in a
CC       conformational change and a subsequent autophosphorylation on several
CC       serine and/or threonine residues (PubMed:7744004). Full-length PAK2
CC       stimulates cell survival and cell growth (PubMed:7744004).
CC       Phosphorylates MAPK4 and MAPK6 and activates the downstream target
CC       MAPKAPK5, a regulator of F-actin polymerization and cell migration
CC       (PubMed:21317288). Phosphorylates JUN and plays an important role in
CC       EGF-induced cell proliferation (PubMed:21177766). Phosphorylates many
CC       other substrates including histone H4 to promote assembly of H3.3 and
CC       H4 into nucleosomes, BAD, ribosomal protein S6, or MBP
CC       (PubMed:21724829). Phosphorylates CASP7, thereby preventing its
CC       activity (PubMed:21555521, PubMed:27889207). Additionally, associates
CC       with ARHGEF7 and GIT1 to perform kinase-independent functions such as
CC       spindle orientation control during mitosis (PubMed:19273597,
CC       PubMed:19923322). On the other hand, apoptotic stimuli such as DNA
CC       damage lead to caspase-mediated cleavage of PAK2, generating PAK-2p34,
CC       an active p34 fragment that translocates to the nucleus and promotes
CC       cellular apoptosis involving the JNK signaling pathway (PubMed:9171063,
CC       PubMed:12853446, PubMed:16617111). Caspase-activated PAK2
CC       phosphorylates MKNK1 and reduces cellular translation
CC       (PubMed:15234964). {ECO:0000269|PubMed:12853446,
CC       ECO:0000269|PubMed:15234964, ECO:0000269|PubMed:16617111,
CC       ECO:0000269|PubMed:19273597, ECO:0000269|PubMed:19923322,
CC       ECO:0000269|PubMed:21177766, ECO:0000269|PubMed:21317288,
CC       ECO:0000269|PubMed:21555521, ECO:0000269|PubMed:21724829,
CC       ECO:0000269|PubMed:27889207, ECO:0000269|PubMed:7744004,
CC       ECO:0000269|PubMed:9171063}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1;
CC         Evidence={ECO:0000269|PubMed:15234964, ECO:0000269|PubMed:21177766,
CC         ECO:0000269|PubMed:21317288, ECO:0000269|PubMed:21555521,
CC         ECO:0000269|PubMed:21724829, ECO:0000269|PubMed:27889207};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:17990;
CC         Evidence={ECO:0000269|PubMed:15234964, ECO:0000269|PubMed:21177766,
CC         ECO:0000269|PubMed:21317288, ECO:0000269|PubMed:21724829,
CC         ECO:0000269|PubMed:27889207};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
CC         Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.11.1; Evidence={ECO:0000269|PubMed:15234964,
CC         ECO:0000269|PubMed:21177766, ECO:0000269|PubMed:21317288,
CC         ECO:0000269|PubMed:21555521, ECO:0000269|PubMed:21724829,
CC         ECO:0000269|PubMed:27889207};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:46609;
CC         Evidence={ECO:0000269|PubMed:15234964, ECO:0000269|PubMed:21177766,
CC         ECO:0000269|PubMed:21317288, ECO:0000269|PubMed:21724829,
CC         ECO:0000269|PubMed:27889207};
CC   -!- ACTIVITY REGULATION: Activated by binding small G proteins (By
CC       similarity). Binding of GTP-bound CDC42 or RAC1 to the autoregulatory
CC       region releases monomers from the autoinhibited dimer, enables
CC       phosphorylation of Thr-402 and allows the kinase domain to adopt an
CC       active structure (By similarity). Following caspase cleavage,
CC       autophosphorylated PAK-2p34 is constitutively active (PubMed:9786869).
CC       {ECO:0000250|UniProtKB:Q13153, ECO:0000269|PubMed:9786869}.
CC   -!- SUBUNIT: Interacts tightly with GTP-bound but not GDP-bound CDC42/p21
CC       and RAC1 (PubMed:20696164). Interacts with SH3MD4 (PubMed:16374509).
CC       Interacts with SCRIB (PubMed:18716323). Interacts with ARHGEF7 and GIT1
CC       (PubMed:19273597). PAK-2p34 interacts with ARHGAP10 (PubMed:15471851).
CC       {ECO:0000269|PubMed:15471851, ECO:0000269|PubMed:16374509,
CC       ECO:0000269|PubMed:18716323, ECO:0000269|PubMed:19273597,
CC       ECO:0000269|PubMed:20696164}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with and activated by HIV-1
CC       Nef. {ECO:0000269|PubMed:11070003}.
CC   -!- INTERACTION:
CC       Q13177; Q9NYB9-2: ABI2; NbExp=3; IntAct=EBI-1045887, EBI-11096309;
CC       Q13177; Q15052: ARHGEF6; NbExp=5; IntAct=EBI-1045887, EBI-1642523;
CC       Q13177; Q14155: ARHGEF7; NbExp=4; IntAct=EBI-1045887, EBI-717515;
CC       Q13177; P55210: CASP7; NbExp=6; IntAct=EBI-1045887, EBI-523958;
CC       Q13177; P60953: CDC42; NbExp=8; IntAct=EBI-1045887, EBI-81752;
CC       Q13177; P62993: GRB2; NbExp=2; IntAct=EBI-1045887, EBI-401755;
CC       Q13177; P08631: HCK; NbExp=2; IntAct=EBI-1045887, EBI-346340;
CC       Q13177; P42858: HTT; NbExp=2; IntAct=EBI-1045887, EBI-466029;
CC       Q13177; P53667: LIMK1; NbExp=2; IntAct=EBI-1045887, EBI-444403;
CC       Q13177; P16333: NCK1; NbExp=5; IntAct=EBI-1045887, EBI-389883;
CC       Q13177; O43639: NCK2; NbExp=8; IntAct=EBI-1045887, EBI-713635;
CC       Q13177; Q13177: PAK2; NbExp=3; IntAct=EBI-1045887, EBI-1045887;
CC       Q13177; P63000: RAC1; NbExp=5; IntAct=EBI-1045887, EBI-413628;
CC       Q13177; P04049: RAF1; NbExp=2; IntAct=EBI-1045887, EBI-365996;
CC       Q13177; Q9H4E5: RHOJ; NbExp=6; IntAct=EBI-1045887, EBI-6285694;
CC       Q13177; Q8TEJ3: SH3RF3; NbExp=2; IntAct=EBI-1045887, EBI-7975674;
CC       Q13177; Q9BX66: SORBS1; NbExp=2; IntAct=EBI-1045887, EBI-433642;
CC       Q13177; O94875: SORBS2; NbExp=2; IntAct=EBI-1045887, EBI-311323;
CC       Q13177; O60504: SORBS3; NbExp=6; IntAct=EBI-1045887, EBI-741237;
CC       Q13177; P12931: SRC; NbExp=2; IntAct=EBI-1045887, EBI-621482;
CC       Q13177; O55043: Arhgef7; Xeno; NbExp=8; IntAct=EBI-1045887, EBI-3649585;
CC       Q13177; Q5PP90: US3(L); Xeno; NbExp=2; IntAct=EBI-1045887, EBI-15780451;
CC   -!- SUBCELLULAR LOCATION: [Serine/threonine-protein kinase PAK 2]:
CC       Cytoplasm {ECO:0000269|PubMed:19923322, ECO:0000269|PubMed:21555521}.
CC       Nucleus {ECO:0000269|PubMed:12853446, ECO:0000269|PubMed:21555521}.
CC       Note=MYO18A mediates the cellular distribution of the PAK2-ARHGEF7-GIT1
CC       complex to the inner surface of the cell membrane.
CC       {ECO:0000269|PubMed:19923322}.
CC   -!- SUBCELLULAR LOCATION: [PAK-2p34]: Nucleus
CC       {ECO:0000269|PubMed:12853446}. Cytoplasm, perinuclear region
CC       {ECO:0000269|PubMed:15471851}. Membrane {ECO:0000269|PubMed:16617111};
CC       Lipid-anchor {ECO:0000269|PubMed:16617111}. Note=Interaction with
CC       ARHGAP10 probably changes PAK-2p34 location to cytoplasmic perinuclear
CC       region (PubMed:15471851). Myristoylation changes PAK-2p34 location to
CC       the membrane (PubMed:16617111). {ECO:0000269|PubMed:15471851,
CC       ECO:0000269|PubMed:16617111}.
CC   -!- TISSUE SPECIFICITY: Ubiquitously expressed. Higher levels seen in
CC       skeletal muscle, ovary, thymus and spleen.
CC       {ECO:0000269|PubMed:7744004}.
CC   -!- PTM: Full-length PAK2 is autophosphorylated when activated by
CC       CDC42/p21. Following cleavage, both peptides, PAK-2p27 and PAK-2p34,
CC       become highly autophosphorylated, with PAK-2p27 being phosphorylated on
CC       serine and PAK-2p34 on threonine residues, respectively.
CC       Autophosphorylation of PAK-2p27 can occur in the absence of any
CC       effectors and is dependent on phosphorylation of Thr-402, because PAK-
CC       2p27 is acting as an exogenous substrate. {ECO:0000269|PubMed:21098037,
CC       ECO:0000269|PubMed:7673144, ECO:0000269|PubMed:9786869}.
CC   -!- PTM: During apoptosis proteolytically cleaved by caspase-3 or caspase-
CC       3-like proteases to yield active PAK-2p34.
CC       {ECO:0000269|PubMed:12853446, ECO:0000269|PubMed:9171063,
CC       ECO:0000269|PubMed:9786869}.
CC   -!- PTM: Ubiquitinated, leading to its proteasomal degradation.
CC       {ECO:0000269|PubMed:12853446}.
CC   -!- PTM: [PAK-2p34]: PAK-2p34 is myristoylated.
CC       {ECO:0000269|PubMed:16617111}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thr
CC       protein kinase family. STE20 subfamily. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/PAK2ID41634ch3q29.html";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U24153; AAA65442.1; -; mRNA.
DR   EMBL; BC069613; AAH69613.1; -; mRNA.
DR   EMBL; U25975; AAA75468.1; -; mRNA.
DR   CCDS; CCDS3321.1; -.
DR   PIR; S58682; S58682.
DR   RefSeq; NP_002568.2; NM_002577.4.
DR   RefSeq; XP_011511172.1; XM_011512870.2.
DR   RefSeq; XP_016861990.1; XM_017006501.1.
DR   PDB; 3PCS; X-ray; 2.86 A; E/F/G/H=121-136.
DR   PDBsum; 3PCS; -.
DR   AlphaFoldDB; Q13177; -.
DR   SMR; Q13177; -.
DR   BioGRID; 111098; 150.
DR   DIP; DIP-38249N; -.
DR   ELM; Q13177; -.
DR   IntAct; Q13177; 73.
DR   MINT; Q13177; -.
DR   STRING; 9606.ENSP00000314067; -.
DR   BindingDB; Q13177; -.
DR   ChEMBL; CHEMBL4487; -.
DR   DrugBank; DB12010; Fostamatinib.
DR   DrugCentral; Q13177; -.
DR   GuidetoPHARMACOLOGY; 2134; -.
DR   GlyGen; Q13177; 3 sites, 1 O-linked glycan (2 sites).
DR   iPTMnet; Q13177; -.
DR   MetOSite; Q13177; -.
DR   PhosphoSitePlus; Q13177; -.
DR   SwissPalm; Q13177; -.
DR   BioMuta; PAK2; -.
DR   DMDM; 143811432; -.
DR   OGP; Q13177; -.
DR   CPTAC; CPTAC-1628; -.
DR   CPTAC; CPTAC-1726; -.
DR   EPD; Q13177; -.
DR   jPOST; Q13177; -.
DR   MassIVE; Q13177; -.
DR   MaxQB; Q13177; -.
DR   PaxDb; Q13177; -.
DR   PeptideAtlas; Q13177; -.
DR   PRIDE; Q13177; -.
DR   ProteomicsDB; 59208; -.
DR   Antibodypedia; 3583; 866 antibodies from 42 providers.
DR   DNASU; 5062; -.
DR   Ensembl; ENST00000327134.7; ENSP00000314067.3; ENSG00000180370.10.
DR   GeneID; 5062; -.
DR   KEGG; hsa:5062; -.
DR   MANE-Select; ENST00000327134.7; ENSP00000314067.3; NM_002577.4; NP_002568.2.
DR   UCSC; uc003fwy.4; human.
DR   CTD; 5062; -.
DR   DisGeNET; 5062; -.
DR   GeneCards; PAK2; -.
DR   HGNC; HGNC:8591; PAK2.
DR   HPA; ENSG00000180370; Low tissue specificity.
DR   MIM; 605022; gene.
DR   neXtProt; NX_Q13177; -.
DR   OpenTargets; ENSG00000180370; -.
DR   PharmGKB; PA32918; -.
DR   VEuPathDB; HostDB:ENSG00000180370; -.
DR   eggNOG; KOG0578; Eukaryota.
DR   GeneTree; ENSGT00950000182988; -.
DR   HOGENOM; CLU_000288_26_6_1; -.
DR   InParanoid; Q13177; -.
DR   OMA; IMMMEMA; -.
DR   OrthoDB; 757766at2759; -.
DR   PhylomeDB; Q13177; -.
DR   TreeFam; TF105351; -.
DR   BRENDA; 2.7.11.1; 2681.
DR   PathwayCommons; Q13177; -.
DR   Reactome; R-HSA-164944; Nef and signal transduction.
DR   Reactome; R-HSA-202433; Generation of second messenger molecules.
DR   Reactome; R-HSA-211728; Regulation of PAK-2p34 activity by PS-GAP/RHG10.
DR   Reactome; R-HSA-211733; Regulation of activated PAK-2p34 by proteasome mediated degradation.
DR   Reactome; R-HSA-211736; Stimulation of the cell death response by PAK-2p34.
DR   Reactome; R-HSA-2871796; FCERI mediated MAPK activation.
DR   Reactome; R-HSA-389359; CD28 dependent Vav1 pathway.
DR   Reactome; R-HSA-3928664; Ephrin signaling.
DR   Reactome; R-HSA-399954; Sema3A PAK dependent Axon repulsion.
DR   Reactome; R-HSA-428540; Activation of RAC1.
DR   Reactome; R-HSA-4420097; VEGFA-VEGFR2 Pathway.
DR   Reactome; R-HSA-445355; Smooth Muscle Contraction.
DR   Reactome; R-HSA-5218920; VEGFR2 mediated vascular permeability.
DR   Reactome; R-HSA-5621575; CD209 (DC-SIGN) signaling.
DR   Reactome; R-HSA-5627123; RHO GTPases activate PAKs.
DR   Reactome; R-HSA-5687128; MAPK6/MAPK4 signaling.
DR   Reactome; R-HSA-8950505; Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation.
DR   Reactome; R-HSA-9013148; CDC42 GTPase cycle.
DR   Reactome; R-HSA-9013149; RAC1 GTPase cycle.
DR   Reactome; R-HSA-9013404; RAC2 GTPase cycle.
DR   Reactome; R-HSA-9013406; RHOQ GTPase cycle.
DR   Reactome; R-HSA-9013407; RHOH GTPase cycle.
DR   Reactome; R-HSA-9013408; RHOG GTPase cycle.
DR   Reactome; R-HSA-9013409; RHOJ GTPase cycle.
DR   Reactome; R-HSA-9013420; RHOU GTPase cycle.
DR   Reactome; R-HSA-9013423; RAC3 GTPase cycle.
DR   Reactome; R-HSA-9013424; RHOV GTPase cycle.
DR   SignaLink; Q13177; -.
DR   SIGNOR; Q13177; -.
DR   BioGRID-ORCS; 5062; 106 hits in 1117 CRISPR screens.
DR   ChiTaRS; PAK2; human.
DR   EvolutionaryTrace; Q13177; -.
DR   GeneWiki; PAK2; -.
DR   GenomeRNAi; 5062; -.
DR   Pharos; Q13177; Tchem.
DR   PRO; PR:Q13177; -.
DR   Proteomes; UP000005640; Chromosome 3.
DR   RNAct; Q13177; protein.
DR   Bgee; ENSG00000180370; Expressed in ganglionic eminence and 208 other tissues.
DR   ExpressionAtlas; Q13177; baseline and differential.
DR   Genevisible; Q13177; HS.
DR   GO; GO:0005911; C:cell-cell junction; IMP:ARUK-UCL.
DR   GO; GO:0005737; C:cytoplasm; IDA:BHF-UCL.
DR   GO; GO:0005829; C:cytosol; IDA:CAFA.
DR   GO; GO:0098978; C:glutamatergic synapse; IEA:Ensembl.
DR   GO; GO:0005634; C:nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0014069; C:postsynaptic density; IEA:Ensembl.
DR   GO; GO:0030141; C:secretory granule; IEA:Ensembl.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0045296; F:cadherin binding; HDA:BHF-UCL.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0004672; F:protein kinase activity; TAS:ProtInc.
DR   GO; GO:0019901; F:protein kinase binding; IPI:BHF-UCL.
DR   GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:BHF-UCL.
DR   GO; GO:0030296; F:protein tyrosine kinase activator activity; IDA:BHF-UCL.
DR   GO; GO:0031267; F:small GTPase binding; IPI:CAFA.
DR   GO; GO:0034333; P:adherens junction assembly; IMP:ARUK-UCL.
DR   GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW.
DR   GO; GO:0070830; P:bicellular tight junction assembly; IMP:ARUK-UCL.
DR   GO; GO:0003300; P:cardiac muscle hypertrophy; IEA:Ensembl.
DR   GO; GO:0071407; P:cellular response to organic cyclic compound; IEA:Ensembl.
DR   GO; GO:0071560; P:cellular response to transforming growth factor beta stimulus; IEA:Ensembl.
DR   GO; GO:0060996; P:dendritic spine development; IEA:Ensembl.
DR   GO; GO:0035556; P:intracellular signal transduction; IBA:GO_Central.
DR   GO; GO:0051179; P:localization; IMP:DisProt.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IMP:UniProtKB.
DR   GO; GO:2001271; P:negative regulation of cysteine-type endopeptidase activity involved in execution phase of apoptosis; IDA:UniProtKB.
DR   GO; GO:0006469; P:negative regulation of protein kinase activity; TAS:ProtInc.
DR   GO; GO:0051497; P:negative regulation of stress fiber assembly; IMP:ARUK-UCL.
DR   GO; GO:0018105; P:peptidyl-serine phosphorylation; IDA:BHF-UCL.
DR   GO; GO:0016310; P:phosphorylation; IDA:UniProtKB.
DR   GO; GO:2001238; P:positive regulation of extrinsic apoptotic signaling pathway; IMP:UniProtKB.
DR   GO; GO:0050731; P:positive regulation of peptidyl-tyrosine phosphorylation; IDA:BHF-UCL.
DR   GO; GO:0046777; P:protein autophosphorylation; IDA:MGI.
DR   GO; GO:0150105; P:protein localization to cell-cell junction; IMP:ARUK-UCL.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:MGI.
DR   GO; GO:0050770; P:regulation of axonogenesis; IBA:GO_Central.
DR   GO; GO:0051493; P:regulation of cytoskeleton organization; IMP:ARUK-UCL.
DR   GO; GO:0043408; P:regulation of MAPK cascade; IBA:GO_Central.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   GO; GO:0002223; P:stimulatory C-type lectin receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0048010; P:vascular endothelial growth factor receptor signaling pathway; TAS:Reactome.
DR   CDD; cd01093; CRIB_PAK_like; 1.
DR   CDD; cd06655; STKc_PAK2; 1.
DR   Gene3D; 3.90.810.10; -; 1.
DR   IDEAL; IID00244; -.
DR   InterPro; IPR000095; CRIB_dom.
DR   InterPro; IPR036936; CRIB_dom_sf.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR035065; PAK2.
DR   InterPro; IPR033923; PAK_BD.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   InterPro; IPR035064; STK_PAK2.
DR   PANTHER; PTHR45832:SF1; PTHR45832:SF1; 1.
DR   Pfam; PF00786; PBD; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00285; PBD; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS50108; CRIB; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Allosteric enzyme; Apoptosis; ATP-binding;
KW   Cytoplasm; Direct protein sequencing; Growth regulation;
KW   Host-virus interaction; Kinase; Lipoprotein; Membrane; Myristate;
KW   Nucleotide-binding; Nucleus; Phosphoprotein; Reference proteome;
KW   Serine/threonine-protein kinase; Transferase; Ubl conjugation.
FT   INIT_MET        1
FT                   /note="Removed"
FT                   /evidence="ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:22223895,
FT                   ECO:0007744|PubMed:22814378"
FT   CHAIN           2..524
FT                   /note="Serine/threonine-protein kinase PAK 2"
FT                   /id="PRO_0000086465"
FT   CHAIN           2..212
FT                   /note="PAK-2p27"
FT                   /id="PRO_0000304922"
FT   CHAIN           213..524
FT                   /note="PAK-2p34"
FT                   /id="PRO_0000304923"
FT   DOMAIN          74..87
FT                   /note="CRIB"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00057"
FT   DOMAIN          249..499
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   REGION          1..81
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          69..137
FT                   /note="Autoregulatory region"
FT                   /evidence="ECO:0000250|UniProtKB:Q13153"
FT   REGION          69..112
FT                   /note="GTPase-binding"
FT                   /evidence="ECO:0000250|UniProtKB:Q13153"
FT   REGION          143..164
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          169..188
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOTIF           245..251
FT                   /note="Nuclear localization signal"
FT                   /evidence="ECO:0000269|PubMed:12853446"
FT   COMPBIAS        41..78
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        367
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10027"
FT   BINDING         255..263
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         278
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   SITE            212..213
FT                   /note="Cleavage; by caspase-3 or caspase-3-like proteases"
FT                   /evidence="ECO:0000269|PubMed:9171063,
FT                   ECO:0000269|PubMed:9786869"
FT   MOD_RES         2
FT                   /note="N-acetylserine"
FT                   /evidence="ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:22223895,
FT                   ECO:0007744|PubMed:22814378"
FT   MOD_RES         2
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17081983,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         20
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         55
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         58
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         60
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         62
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8CIN4"
FT   MOD_RES         64
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         128
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         134
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         139
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   MOD_RES         141
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163,
FT                   ECO:0007744|PubMed:24275569"
FT   MOD_RES         143
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         152
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8CIN4"
FT   MOD_RES         154
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         169
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163"
FT   MOD_RES         197
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19690332,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         402
FT                   /note="Phosphothreonine; by autocatalysis"
FT                   /evidence="ECO:0000305|PubMed:9786869"
FT   LIPID           213
FT                   /note="N-myristoyl glycine; in form PAK-2p34"
FT                   /evidence="ECO:0000269|PubMed:16617111"
FT   MUTAGEN         212
FT                   /note="D->N: Inhibits caspase-mediated cleavage."
FT                   /evidence="ECO:0000269|PubMed:9171063"
FT   MUTAGEN         213
FT                   /note="G->A: Abolishes myristoylation of PAK-2p34 and
FT                   membrane location."
FT                   /evidence="ECO:0000269|PubMed:16617111"
FT   MUTAGEN         239..243
FT                   /note="IVSIG->REGRS: Abolishes nuclear export."
FT                   /evidence="ECO:0000269|PubMed:12853446"
FT   MUTAGEN         246..248
FT                   /note="KKK->MHE: Greatly inhibits nuclear localization."
FT                   /evidence="ECO:0000269|PubMed:12853446"
FT   MUTAGEN         278
FT                   /note="K->R: Abolishes kinase activity and
FT                   autophosphorylation."
FT                   /evidence="ECO:0000269|PubMed:9786869"
FT   MUTAGEN         402
FT                   /note="T->A: Abolishes kinase activity and greatly inhibits
FT                   autophosphorylation of PAK-2p27 and PAK-2p34."
FT                   /evidence="ECO:0000269|PubMed:9786869"
FT   CONFLICT        90
FT                   /note="A -> T (in Ref. 3; AAA75468)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        150
FT                   /note="F -> L (in Ref. 1; AAA65442)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        225
FT                   /note="T -> P (in Ref. 1; AAA65442)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        258
FT                   /note="G -> R (in Ref. 2; AAH69613)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        329
FT                   /note="G -> R (in Ref. 3; AAA75468)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        338
FT                   /note="T -> TA (in Ref. 1; AAA65442)"
FT                   /evidence="ECO:0000305"
FT   HELIX           123..126
FT                   /evidence="ECO:0007829|PDB:3PCS"
SQ   SEQUENCE   524 AA;  58043 MW;  00A7CD15F93D4180 CRC64;
     MSDNGELEDK PPAPPVRMSS TIFSTGGKDP LSANHSLKPL PSVPEEKKPR HKIISIFSGT
     EKGSKKKEKE RPEISPPSDF EHTIHVGFDA VTGEFTGMPE QWARLLQTSN ITKLEQKKNP
     QAVLDVLKFY DSNTVKQKYL SFTPPEKDGF PSGTPALNAK GTEAPAVVTE EEDDDEETAP
     PVIAPRPDHT KSIYTRSVID PVPAPVGDSH VDGAAKSLDK QKKKTKMTDE EIMEKLRTIV
     SIGDPKKKYT RYEKIGQGAS GTVFTATDVA LGQEVAIKQI NLQKQPKKEL IINEILVMKE
     LKNPNIVNFL DSYLVGDELF VVMEYLAGGS LTDVVTETCM DEAQIAAVCR ECLQALEFLH
     ANQVIHRDIK SDNVLLGMEG SVKLTDFGFC AQITPEQSKR STMVGTPYWM APEVVTRKAY
     GPKVDIWSLG IMAIEMVEGE PPYLNENPLR ALYLIATNGT PELQNPEKLS PIFRDFLNRC
     LEMDVEKRGS AKELLQHPFL KLAKPLSSLT PLIMAAKEAM KSNR
//
